Shilpa Medicare Achieves Record Revenue and Profit in Q1 FY27

1QFY27 Revenue: ₹469 crore
1QFY27 PAT: ₹101 crore

Reader Takeaway: Record revenue and PAT signal strong operational execution, while regulatory delays pose a watch point.

What just happened

Shilpa Medicare has announced its financial results for the first quarter of FY27 (1QFY27), reporting a record quarterly revenue of ₹469 crore, marking a significant 43% year-on-year increase from ₹328 crore in 1QFY26. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) rose by 42% to ₹139 crore. The company's Profit After Tax (PAT) saw a substantial jump of 115%, reaching ₹101 crore compared to ₹47 crore in the prior year's corresponding quarter.

Why this matters

The strong financial performance indicates robust growth across Shilpa Medicare's key business segments and improved operational efficiencies. The record revenue and significant PAT growth demonstrate the company's ability to capitalize on market opportunities and effectively manage its operations, which is positive for shareholder value.

The backstory

In the previous fiscal year, Shilpa Medicare had been focusing on strengthening its core businesses and expanding its capacities. The company has been investing in its API, Formulations, and Biologics segments, aiming for integrated service offerings. This quarter's results reflect the benefits of these strategic initiatives and ongoing capacity expansions.

What changes now

With record results and a credit rating upgrade to AA-, Shilpa Medicare is better positioned financially. The company is proceeding with capacity expansions, including new facilities for Onco block, Peptide synthesis, and ADC. Strategic partnerships for albumin and brain cancer assets also signal future growth avenues.

Risks to watch

Investors should monitor the company's reliance on regulatory approvals from the US and EU for future revenue growth. Additionally, a delay in the OLC NDA due to deficiencies at a third-party manufacturing facility is a concern that could impact commercialization timelines.

Peer comparison

While specific peer financials for 1QFY27 are not yet available, Shilpa Medicare's reported growth rates and margins in API and Formulations are generally competitive within the Indian pharmaceutical sector. The company's focus on specialty CDMO services and biologics also positions it in high-growth niches.

Context metrics (time-bound)

• 1QFY27 Revenue: ₹469 crore (up 43% YoY)
• 1QFY27 EBITDA: ₹139 crore (up 42% YoY)
• 1QFY27 PAT: ₹101 crore (up 115% YoY)
• Adjusted ROCE (TTM): 18.3%
• Net Debt to EBITDA: 1.3x

What to track next

Investors will be keen to track the ramp-up of new manufacturing capacities, the progress of the company's novel pipeline including Recombinant Human Albumin and ADC products, and the resolution of regulatory milestones for key products like OLC.